Securities Times News On the evening of February 24, Erkang Pharmaceutical (300267) announced that its holding subsidiary Hunan Erkang Xiang Pharmaceutical Co., Ltd. (hereinafter referred to as “Xiang Yao Pharmaceutical”) was recently approved by Hunan Provincial Drug Administration. 2 copies of the drug supplement application issued. The supplement application of the capsule is to increase the hydroxypropyl starch hollow capsule into a capsule shell of amoxicillin and ranitidine hydrochloride.

The starch wholesale manufacturer said that the approval of the drug supplement application means that all the domestic approval procedures for the direct application of hydroxypropyl starch hollow capsules to amoxicillin capsules and ranitidine hydrochloride capsules have been completed and can be directly used in production. And sales.

The acquisition of the above-mentioned approvals will prompt the starch hard capsules to seize the capsule market which has been relatively shrinking due to the "poison capsule" incident in recent years. With the use of the generic capsules of starch capsules, it is expected to become a new growth point.

In the case of amoxicillin alone, the traditional gelatin capsule shell used in the domestic drug is more than 20 billion capsules per year.

Backtracking announcements reveal that companies have long been in the field. On October 1, 2015, the company announced that its holding subsidiary, Xiangyao Pharmaceutical Co., plans to use its own funds of 41.8 million yuan to invest in the construction of an annual output of 8.4 billion starch capsule preparation workshops.

According to the company, the starch plant capsule products are currently used in the production of amoxicillin capsules, and have entered the equipment commissioning stage. The production capacity of 8.4 billion starch capsule preparations will gradually reach production according to market demand.